IP Library Granted Patent US 6,852,488
Granted Patent B2
US 6,852,488 · App. 09/776,768 · Granted Feb 8, 2005

Identifying a base in a nucleic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,852,488
App. No.
09/776,768
Granted
Feb 8, 2005
Kind
B2
Abstract

Devices and techniques for hybridization of nucleic acids and for determining the sequence of nucleic acids. Arrays of nucleic acids are formed by techniques, preferably high resolution, light-directed techniques. Positions of hybridization of a target nucleic acid are determined by, e.g., epifluorescence microscopy. Devices and techniques are proposed to determine the sequence of a target nucleic acid more efficiently and more quickly through such synthesis and detection techniques.

Claims (27)

1. A method of detecting a mutation in a target nucleic acid sequence versus a known sequence comprising:

a) exposing the target sequence to at least one known core sequence probe;

b) determining the binding affinity of the target sequence to the at least one known core sequence probe;

c) determining the binding affinity of the target sequence to at least one probe that has a single nucleotide variation as compared to the at least one known core sequence probe; and

d) comparing the binding affinity determined in step b) to the binding affinity determined in step c);

thereby detecting a mutation in a target nucleic acid sequence versus a known sequence.

2. A method of claim 1 , wherein the at least one known core sequence probe is an array of known core sequence probes.

3. A method of claim 1 , further comprising before step a), identifying one or more core sequences which are present within the known sequence and would be expected to have high affinity to the target sequence if the target sequence does not contain a mutation.

4. A method of claim 1 , wherein the binding affinity to the known core sequence probe is plotted as affinity versus mismatch position, and normalized to the affinity of a perfect complement of the known core sequence probe.

5. A method of claim 4 , further comprising determining that the target sequence comprises a mutation versus the known sequence if the pattern formed by the normalized affinity plot of the target sequence does not match the pattern formed by an affinity plot of the perfect complement.

6. A method of claim 1 , further comprising determining if the binding affinity of the target sequence to the at least one known core sequence probe is weaker than the binding affinity of the known sequence to the at least one known core sequence probe.

7. A method of claim 1 , wherein the at least one probe is between about 5 and 100 bases in length.

8. A method of claim 7 , wherein the at least one probe is between about 5 and 50 bases in length.

9. A method of claim 8 , wherein the at least one probe is between about 8 and 30 bases in length.

10. A method of claim 9 , wherein the at least one probe is between about 8 and 15 bases in length.

11. A method of claim 1 , wherein the mutation in the target sequence is indicative of a genetic disease.

12. A method of claim 11 , wherein the genetic disease is sickle cell anemia.

13. A method of claim 11 , wherein the genetic disease is cystic fibrosis.

14. A method of claim 11 , wherein the genetic disease is associated with a P-53 mutation.

15. A method of claim 1 , wherein the mutation in the target sequence is indicative of a genetic predisposition.

16. A method of claim 15 , wherein the genetic predisposition is associated with a particular HLA Class I or HLA Class II gene.

17. A method of claim 15 , wherein the ELA Class II gene is selected from the group consisting of DP, DQ and DR beta.

18. A method of claim 1 , wherein detecting a mutation in the target sequence is comprised in a genetic evaluation.

19. A method of claim 18 , wherein the genetic evaluation is a forensics evaluation.

20. The method of claim 1 , wherein the binding affinity in step b) and c) is absolute binding affinity.

21. A method of claim 25, wherein said at least one probe having a single nucleotide variation as compared to the at least one known core sequence probe is made by substituting A, C, T, U or G at each position of the at least one known core sequence probe.

22. A method of claim 1 , wherein the at least one core sequence probe or the at least one probe is attached to a bead.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Nov 13, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
To: AFFYMETRIX, INC.
Reel/Frame 037109/0132 →
SECURITY AGREEMENT Recorded Jun 27, 2012
From: AFFYMETRIX, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 028465/0541 →